BioMarin snares orphan drug upstart in $115M buyout

Continuing its year-long buying spree, BioMarin Pharmaceutical has agreed to pay up to $115 million to snare ZyStor Therapeutics and its preclinical candidate for Pompe disease. BioMarin is slapping down $22 million upfront to seal the deal, which will add an enzyme therapy scheduled to enter the clinic next year. The FDA has already approved ZyStor's IND app for ZC-701. And Novato, CA-based BioMarin, which specializes in orphan diseases, is pumped about its prospects. The deal "not only...

TheStreet tracks the top 10 clinical trials to watch

TheStreet's top biotech stock ace, Adam Feuerstein, has culled through a mountain of releases and reports to come up with the 10 most closely-watched trial announcements expected in the second half of the year. His list includes: Ariad's Phase III data for the sarcoma drug ridaforolimus, which Merck licensed; AstraZeneca's zibotentan, which hopes to answer the question about who has the next Provenge to offer the market; as well as mid-stage data on BioMarin's Peg-Pal for phenylketonuria,...